Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532764 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients
A Phase 1 study, sponsored by ProQR Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT02532764 is a Phase 1 study that has completed, run by ProQR Therapeutics. The registered enrollment target is 70 participants.
The verdict
NCT02532764, a Phase 1 study, has completed, sponsored by ProQR Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.
Interventions
- DRUG Placebo
- DRUG QR-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02532764
The ClinicalTrials.gov registry entry for NCT02532764 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ProQR Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02532764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02532764 about?
NCT02532764 is a clinical study titled "Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients". A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.
What is the current status of trial NCT02532764?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2015-06. Estimated completion is 2017-09-14.
What interventions are being tested in trial NCT02532764?
The interventions under investigation include: Placebo (DRUG), QR-010 (DRUG).
Who is sponsoring clinical trial NCT02532764?
This trial is sponsored by ProQR Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.